Skip to content

Determination and clinical significance of serum IFN-? and CCL2 in patients with traumatic spinal cord injury

Determination and clinical significance of serum IFN-? and CCL2 in patients with traumatic spinal cord injury

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300074421
Enrollment
Unknown
Registered
2023-08-07
Start date
2023-08-08
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

traumatic spinal cord injury

Interventions

mitigation group G1:none
unmitigated group G2:none

Sponsors

China Rehabilitation Research Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) All patients had traumatic spinal cord injuries due to trauma and were 18-60 years old; (2) The site of damage was cervical or thoracolumbar; (3) They were in the subacute (48h-14d) and intermediate (14d-6 months) phases as defined in the Clinical Treatment Guidelines for Neurorestoration of Spinal Cord Injury (2021 edition); (4) Entered our hospital for treatment no more than 1 month after surgery; (5) Those whose MRI imaging suggests support for the diagnosis and excludes craniocerebral injury; (6) Those with severe disc herniation and/or previous spinal surgery are excluded; (7) Those who do not have significant organ damage such as heart or kidney damage; (8) Those who have no past history of Alzheimer's disease, no mental disorder, consciousness disorder, and language disorder, ideal cooperation, and good communication skills; (9) All patients signed an informed consent form, which was discussed and approved by the Ethics Committee.

Exclusion criteria

Exclusion criteria: (1) With severe malignant lesions, hematopoietic and coagulopathic disorders, immune system diseases; (2) Pregnant or lactating women; (3) People with hypertension, diabetes, or abnormal liver or kidney functions (4) Patients who have not used hormones and other immune agents before the test; (5) Patients with complications such as heterotopic ossification that cause elevated inflammatory indicators.

Design outcomes

Primary

MeasureTime frame
the expression levels of IFN-? and CCL2/MPC-1;ASIA scale scores;

Secondary

MeasureTime frame
SCIM scale scores;

Countries

China

Contacts

Public ContactLi Jun

China Rehabilitation Research Center,Beijing Boai Hospital

jia2021crrc@163.com+86 134 2648 9069

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026